133 related articles for article (PubMed ID: 18711102)
1. Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease.
Guenova E; Weber HO; Voykov B; Metzler G; Mitev V; Berneburg M; Hoetzenecker W; Röcken M
Arch Dermatol; 2008 Aug; 144(8):1081-2. PubMed ID: 18711102
[No Abstract] [Full Text] [Related]
2. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Lipworth AD; Robert C; Zhu AX
Oncology; 2009; 77(5):257-71. PubMed ID: 19923864
[TBL] [Abstract][Full Text] [Related]
3. Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib.
Jiménez-Gallo D; Albarrán-Planelles C; Linares-Barrios M; Martínez-Rodríguez A; Báez-Perea JM
JAMA Dermatol; 2013 May; 149(5):624-6. PubMed ID: 23677103
[No Abstract] [Full Text] [Related]
4. Sunitinib-induced subungual splinter haemorrhage and acral erythema.
Nakamura M; Miyachi Y
Eur J Dermatol; 2008; 18(3):344-5. PubMed ID: 18474471
[No Abstract] [Full Text] [Related]
5. A case of pyoderma gangrenosum possibly associated with sunitinib treatment.
Ueharaguchi Y; Kabashima K; Sasahashi M; Matsuda A; Matubara K; Matsui M
Int J Dermatol; 2013 May; 52(5):634-6. PubMed ID: 23590380
[No Abstract] [Full Text] [Related]
6. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma.
Tsai KY; Yang CH; Kuo TT; Hong HS; Chang JW
J Clin Oncol; 2006 Dec; 24(36):5786-8. PubMed ID: 17179114
[No Abstract] [Full Text] [Related]
7. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.
Chu D; Lacouture ME; Weiner E; Wu S
Clin Genitourin Cancer; 2009 Jan; 7(1):11-9. PubMed ID: 19213662
[TBL] [Abstract][Full Text] [Related]
8. Home blood-pressure monitoring in patients receiving sunitinib.
Azizi M; Chedid A; Oudard S
N Engl J Med; 2008 Jan; 358(1):95-7. PubMed ID: 18172185
[No Abstract] [Full Text] [Related]
9. Lower limbs erosions induced by sunitinib.
Kluger N; Chapelle A; Jacot W; Guillot B
Acta Derm Venereol; 2011 May; 91(3):360-1. PubMed ID: 21103845
[No Abstract] [Full Text] [Related]
10. Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib.
Chorianopoulos E; Jäger D; Katus HA; Frey N
Clin Res Cardiol; 2007 Nov; 96(11):829-30. PubMed ID: 17694380
[No Abstract] [Full Text] [Related]
11. [Cutaneous side effects of sorafenib and sunitinib].
Autier J; Mateus C; Wechsler J; Spatz A; Robert C
Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
[No Abstract] [Full Text] [Related]
12. Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma.
Mermershtain W; Lazarev I; Shani-Shrem N; Ariad S
Clin Genitourin Cancer; 2013 Mar; 11(1):70-2. PubMed ID: 23063577
[No Abstract] [Full Text] [Related]
13. Sunitinib and hypothyroidism.
Wolter P; Dumez H; Schöffski P
N Engl J Med; 2007 Apr; 356(15):1580; author reply 1580-1. PubMed ID: 17429091
[No Abstract] [Full Text] [Related]
14. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
Nicholaou T; Wong R; Davis ID
Lancet; 2007 Jun; 369(9577):1923-4. PubMed ID: 17560435
[No Abstract] [Full Text] [Related]
15. Pyoderma gangrenosum with the use of sunitinib.
Nadauld LD; Miller MB; Srinivas S
J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
[No Abstract] [Full Text] [Related]
16. Skin depigmentation induced by sunitinib treatment of renal cell carcinoma.
Al Enazi MM; Kadry R; Mitwali H
J Am Acad Dermatol; 2009 Nov; 61(5):905-6. PubMed ID: 19836653
[No Abstract] [Full Text] [Related]
17. Sunitinib-aggravated hypertension.
Rivera F; Benounna M; Sánchez de la Nieta MD
J Hypertens; 2009 Jul; 27(7):1502-3. PubMed ID: 19542988
[No Abstract] [Full Text] [Related]
18. Sunitinib-induced hand-foot syndrome in a renal cell carcinoma: a sclerodermatous and rheumatoid arthritis-like case.
Ohtsuka T
J Dermatol; 2012 Nov; 39(11):943-4. PubMed ID: 22257303
[No Abstract] [Full Text] [Related]
19. [Tumor lysis syndrome in a patient with a renal carcinoma treated with sunitinib].
Rodríguez-Reimúndes E; Perazzo F; Vilches AR
Medicina (B Aires); 2011; 71(2):158-60. PubMed ID: 21550933
[TBL] [Abstract][Full Text] [Related]
20. Fatigue with sunitinib-induced hypothyroidism.
Senior K
Lancet Oncol; 2007 Feb; 8(2):101. PubMed ID: 17288042
[No Abstract] [Full Text] [Related]
[Next] [New Search]
